TRACE AMINE-ASSOCIATED RECEPTOR 1 IS A MODULATOR OF BRAIN MONOAMINERGIC SYSTEMS

微量胺相关受体 1 是大脑单胺能系统的调节剂

• 批准号: 8357909
• 负责人: GREGORY MICHAEL MILLER
• 金额: $ 1.64万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357909
• 关键词: Amines; Behavioral; Brain; Disease; Funding; Genetic; Grant; Human; Modeling; National Center for Research Resources; Neurobiology; New England; Physiological; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Rodent; Role; Source; Structure; System; Therapeutic Agents; Transgenic Organisms; United States National Institutes of Health; addiction; base; cost; neuropsychiatry; nonhuman primate; novel; receptor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. As human and rodent trace amine receptors diverge in structure, subtype number and brain distribution, we postulate that non-human primates will provide a more suitable model for uncovering the physiological and pharmacological relevance of trace amine subtypes. In this regard, there is a 96 percent sequence identity for Trace Amine Associated Receptor 1 (TAAR1) in non-human primate and human. We are investigating the fundamental neurobiological roles of TAAR1 in mammalian brain and behavioral effects resulting from its activation or deletion using pharmacological, cellular, genetic, anatomical, transgenic and behavioral approaches. Our studies form the basis for investigating the physiological and pharmacological relevance of trace amine receptors in the primate model, and provide novel leads for developing therapeutic agents to treat addiction and neuropsychiatric disorders.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 由于人类和啮齿类动物的微量胺受体在结构、亚型数量和脑分布上存在差异，我们推测非人类灵长类动物将为揭示微量胺亚型的生理和药理学相关性提供更合适的模型。在这方面，在非人灵长类动物和人类中，痕量胺相关受体1（TAAR 1）具有96%的序列同一性。我们正在研究TAAR 1在哺乳动物大脑中的基本神经生物学作用，以及使用药理学，细胞学，遗传学，解剖学，转基因和行为学方法激活或删除TAAR 1所产生的行为效应。我们的研究形成了研究灵长类动物模型中微量胺受体的生理和药理学相关性的基础，并为开发治疗药物治疗成瘾和神经精神疾病提供了新的线索。